Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Scandinavian Journal of Child and Adolescent Psychiatry and Psychology
|
November 25, 2024
Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet<sup>®</sup> MR and Concerta<sup>®</sup>) - a Danish nationwide register-based cohort study
Jakob Ørnberg, Anke Mayer, Oliver Dangel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
September 4, 2020
Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions
Wolfgang Retz, Michael Rösler, Roland Fischer, et al.
Journal of Child and Adolescent Psychopharmacology
|
July 28, 2011
Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial
Manfred Döpfner, Claudia Ose, Roland Fischer, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
January 24, 2009
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder
Michael Rösler, Roland Fischer, Richard Ammer, et al.
Herz
|
August 22, 2002
[Atrial fibrillation: molecular biology bases]
Wilhelm Haverkamp, Richard Ammer, Paulus Kirchhof, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
December 16, 2010
Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate
Wolfgang Retz, Michael Rösler, Claudia Ose, et al.
CNS Drugs
|
December 13, 2024
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
Yi Zheng, Huaqing Liu, Xiuxia Wang, et al.
Kidney International Reports
|
March 18, 2021
Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial
Markus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, et al.
BMC Psychiatry
|
February 9, 2024
ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?
Sophie Gimbach, Daniel Vogel, Roland Fried, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 29, 2023
The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions
Sophie Gimbach, Daniel Vogel, Roland Fried, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Scandinavian Journal of Child and Adolescent Psychiatry and Psychology
|
November 25, 2024
Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet<sup>®</sup> MR and Concerta<sup>®</sup>) - a Danish nationwide register-based cohort study
Jakob Ørnberg, Anke Mayer, Oliver Dangel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
September 4, 2020
Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions
Wolfgang Retz, Michael Rösler, Roland Fischer, et al.
Journal of Child and Adolescent Psychopharmacology
|
July 28, 2011
Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial
Manfred Döpfner, Claudia Ose, Roland Fischer, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
January 24, 2009
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder
Michael Rösler, Roland Fischer, Richard Ammer, et al.
Herz
|
August 22, 2002
[Atrial fibrillation: molecular biology bases]
Wilhelm Haverkamp, Richard Ammer, Paulus Kirchhof, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
December 16, 2010
Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate
Wolfgang Retz, Michael Rösler, Claudia Ose, et al.
CNS Drugs
|
December 13, 2024
Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
Yi Zheng, Huaqing Liu, Xiuxia Wang, et al.
Kidney International Reports
|
March 18, 2021
Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial
Markus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, et al.
BMC Psychiatry
|
February 9, 2024
ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?
Sophie Gimbach, Daniel Vogel, Roland Fried, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 29, 2023
The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions
Sophie Gimbach, Daniel Vogel, Roland Fried, et al.
Page
of 2